CDKN2A and breast cancer: One study demonstrated that expression of p16INK4a, an inhibitor of cyclin-dependent kinase 4 associated with cellular senescence, increased after adjuvant chemotherapy in 33 patients with breast cancer, and remained elevated 12 months after treatment [42].